Roche Relies on Artificial Intelligence in Diagnostics

Roche Relies on Artificial Intelligence in Diagnostics

Di, 13. Feb. 2024

Roche and PathAI Collaborate on AI Diagnostics in Pathology. Developing AI Algorithms for Digital Pathology Applications. Providing Solutions for Personalized Medicine Development.

Keystone/SDA - GAETAN BALLY

Roche recently acquired LumiraDx, now they working with the US company PathAI in the field of diagnostics. Algorithms for digital pathology with artificial intelligence are to be developed as part of this collaboration.

The collaboration aims to advance precision medicine by bringing together AI interpretation and companion diagnostics, Roche explained in a press release on Tuesday. Roche is developing new innovations for personalized medicine, said Jill German, Head of Roche Tissue Diagnostics.

By working together with PathAI, the demand from biopharma companies can be better met, and an end-to-end solution for developing precision therapies can be offered. The two companies have already created an integrated image analysis workflow for pathologists in a previous collaboration in October 2021.

©Keystone/SDA

Verwandte Geschichten

In Kontakt bleiben

Erwähnenswert

the swiss times
Eine Produktion der UltraSwiss AG, 6340 Baar, Schweiz
Copyright © 2024 UltraSwiss AG 2024 Alle Rechte vorbehalten